Belluscura PLC Belluscura appoints Senior VP of Global Sales
January 16 2023 - 2:00AM
RNS Non-Regulatory
TIDMBELL
Belluscura PLC
16 January 2023
16 January 2023
Belluscura plc
("Belluscura" or the "Company")
Belluscura appoints Senior Vice President of Global Sales
Belluscura plc (AIM: BELL), a leading medical device developer
focused on lightweight and portable oxygen enrichment technology,
announces that Robert ("Bob") Fary has joined the Company as Senior
Vice President of Global Sales.
Bob has thirty-years of experience in the respiratory industry
where he has held leadership roles at major oxygen concentrator
manufacturers and durable medical equipment companies. During the
past two decades, Bob's industry leading team was directly
responsible or contributed to the sale of over 1 million portable
oxygen concentrators ("POCs"), generating revenues in excess of $1
billion.
Commenting on the hire, Robert Rauker, Chief Executive Officer,
Belluscura plc, said:
"We are very excited that Bob has joined our team as we enter
the next stage of growth at Belluscura. His deep knowledge of the
portable oxygen concentrator sector and its channels to market will
be invaluable as we build on our success to date to bring our
latest generation of POCs to market."
Bob Fary, Senior Vice President of Global Sales, commented:
"I am delighted to have joined Belluscura at this important
juncture for the Company as it captures the demand in its markets
for its best-in-class products. The planned launch of DISCOV-R will
be another exciting step in meeting the needs of patients around
the world. I look forward to working alongside the wider executive
team to grow the Company's sales in the US and beyond."
ENDS
For further information, please contact:
Belluscura plc www.belluscura.com
Robert Rauker, Chief Executive via MHP
Officer
Anthony Dyer, Chief Financial
Officer
SPARK Advisory Partners Limited Tel: +44 (0)20 3368 3550
(NOMAD)
Neil Baldwin
Dowgate Capital Limited (Broker) Tel: +44 (0)20 3903 7715
James Serjeant / Nicholas Chambers
MHP (Financial PR and Investor Tel: +44 (0)20 3128 8100
Relations)
Katie Hunt / Pete Lambie / Matthew Email: belluscura@mhpgroup.com
Taylor
About Belluscura plc ( www.belluscura.com )
Belluscura is a UK medical device company focused on developing
high performing, lightweight and portable oxygen enrichment
technology used in a broad range of industries and therapies. Our
innovative oxygen technologies are designed with a global purpose:
to create improved health, mobility and economic outcomes for
patients, healthcare providers and insurance organisations.
About RNS Reach announcements
Reach is an investor communication service aimed at assisting
listed and unlisted (including AIM quoted) companies to distribute
media only / non-regulatory news releases such as marketing
messages, corporate and product information into the public domain.
An RNS Regulatory announcement is required to be notified under the
AIM Rules for Companies.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEAPFSFDFDEFA
(END) Dow Jones Newswires
January 16, 2023 02:00 ET (07:00 GMT)
Belluscura (LSE:BELL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Belluscura (LSE:BELL)
Historical Stock Chart
From Apr 2023 to Apr 2024